<DOC>
	<DOCNO>NCT02609581</DOCNO>
	<brief_summary>To expand knowledge application tolerability immunotherapy LAIS速 Mites allergoid tablet well knowledge alleviation symptom sublingual therapy special consideration choose titration schedule everyday practice .</brief_summary>
	<brief_title>Tolerability SLIT With LAIS速 Mites Allergoid Tablets</brief_title>
	<detailed_description>Until , result control study specific requirement ( patient selection , define inclusion exclusion criterion , close patient management monitoring , randomisation ) available LAIS速 Mites allergoid tablet small patient population . In addition , open-label , control study observational study carry investigate clinical efficacy tolerability preparation . Owing difference study design , allergen dose administer frequency preparation apply varied among individual study , make necessary gather data safety tolerability preparation large patient population . The observation schedule NIS ( NIS accordance Article 67 Paragraph 6 German Medicinal Products Act ( AMG ) ) , take account recommendation make German Federal Institute Drugs Medical Devices ( BfArM ) Paul Ehrlich Institute planning , implement evaluate NIS , gear routine procedure carry patient allergy tree pollen . The aim observational study observe document tolerability improvement symptom treatment LAIS速 Mites allergoid tablet normal application condition consideration choose titration schedule therapeutic practice - accordance patient information leaflet - large patient population : Retrospective survey rhinitis/rhinoconjunctivitis symptom induce tree pollen Overall symptomatology Documentation restriction cause allergy/asthma Tolerability treatment mean AE documentation Patient compliance Additional requirement extend beyond specification list patient information leaflet product use , patient group , dosage , contraindication , etc. , make .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Patients age 18 year old allergy within scope specification state patient information leaflet Contraindications accord patient information leaflet</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non Interventional Study</keyword>
	<keyword>NIS</keyword>
	<keyword>sublingual immunotherapy</keyword>
	<keyword>allergen</keyword>
	<keyword>Mites</keyword>
</DOC>